Research Analysts Offer Predictions for DNLI FY2028 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at HC Wainwright boosted their FY2028 EPS estimates for shares of Denali Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of $4.16 per share for the year, up from their prior estimate of $3.98. HC Wainwright has a "Buy" rating and a $87.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics' FY2029 earnings at $6.29 EPS.

DNLI has been the subject of a number of other reports. Stifel Nicolaus upgraded shares of Denali Therapeutics from a "hold" rating to a "buy" rating and set a $37.00 price objective for the company in a research report on Monday, December 16th. William Blair assumed coverage on shares of Denali Therapeutics in a report on Friday, January 3rd. They issued an "outperform" rating for the company. Raymond James reaffirmed a "market perform" rating on shares of Denali Therapeutics in a report on Thursday, October 10th. Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $31.00 price objective for the company. Finally, JPMorgan Chase & Co. decreased their target price on Denali Therapeutics from $28.00 to $24.00 and set an "overweight" rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $38.91.

Denali Therapeutics Price Performance

DNLI stock traded up $0.07 during mid-day trading on Wednesday, reaching $21.25. 1,245,656 shares of the company traded hands, compared to its average volume of 1,173,671. The company has a fifty day moving average price of $24.34 and a 200-day moving average price of $24.88. Denali Therapeutics has a 52-week low of $14.56 and a 52-week high of $33.33. The company has a market capitalization of $3.06 billion, a P/E ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the firm posted ($0.72) earnings per share.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 15,558 shares of the firm's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $29.91, for a total transaction of $465,339.78. Following the transaction, the insider now directly owns 178,066 shares in the company, valued at $5,325,954.06. This trade represents a 8.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the business's stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at $6,529,495.83. The trade was a 14.50 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 104,518 shares of company stock valued at $2,576,982. Corporate insiders own 7.90% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC boosted its position in Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company's stock valued at $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company's stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Denali Therapeutics during the second quarter worth about $24,454,000. Wellington Management Group LLP grew its stake in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company's stock worth $312,491,000 after purchasing an additional 903,683 shares during the last quarter. Finally, Integral Health Asset Management LLC purchased a new position in Denali Therapeutics during the 2nd quarter valued at about $7,546,000. Institutional investors own 92.92% of the company's stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.